Search Results - "Shore, Neal"

Cellular Immunotherapy for Prostate Cancer: Lessons Learned From 15 Years of Sipuleucel‐T.

Authors: Shore, Neal D. Antonarakis, Emmanuel S. Hafron, Jason et al.

Source: Prostate Cancer (20903111). 12/31/2025, Vol. 2025, p1-15. 15p.

Homologous Recombination Repair Mutations, Next-generation Sequencing Testing, and Treatment Progression by Race Among Patients With Metastatic Castration-sensitive Prostate Cancer.

Authors: Bilen, Mehmet A. Shore, Neal Burbage, Sabree et al.

Source: Urology. May2026, Vol. 211, p43-49. 7p.

Real-world clinical outcomes and economic burden of discontinuation of taxane therapy among patients with metastatic castration-resistant prostate cancer.

Authors: Shore, Neal Nguyen Kang, Barinder et al.

Source: International Journal of Clinical Oncology. Aug2026, Vol. 31 Issue 8, p1451-1471. 21p.

Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer.

Authors: Shore, Neal D. de Almeida Luz, Murilo De Giorgi, Ugo et al.

Source: New England Journal of Medicine. 2/5/2026, Vol. 394 Issue 6, p563-575. 13p.

Transcriptome profiling of prostatic tumours from ENACT trial patients with or without enzalutamide.

Authors: Handa, Nicole Shore, Neal D. Cooperberg, Matthew R. et al.

Source: BJU International. Nov2025, Vol. 136 Issue 5, p920-929. 10p.

Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial.

Authors: Agarwal, Neeraj Azad, Arun A Carles, Joan et al.

Source: Lancet. Aug2025, Vol. 406 Issue 10502, p447-460. 14p.

Subjects: Castration-resistant prostate cancer, Homologous recombination, Clinical trials, Overall survival, Androgen deprivation therapy

Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial.

Authors: Fizazi, Karim Azad, Arun A Matsubara, Nobuaki et al.

Source: Lancet. Aug2025, Vol. 406 Issue 10502, p461-474. 14p.

Subjects: Castration-resistant prostate cancer, Statistical significance, Overall survival, Homologous recombination, Clinical trials

Impact of darolutamide on local symptoms: pre‐planned and post hoc analyses of the ARAMIS trial.

Authors: Shore, Neal D. Stenzl, Arnulf Pieczonka, Christopher et al.

Source: BJU International. Apr2023, Vol. 131 Issue 4, p452-460. 9p.

Implementing and Optimizing Universal Germline Genetic Testing for Patients With Prostate Cancer in Clinical Practice.

Authors: Shore, Neal Armstrong, Andrew J. Barata, Pedro et al.

Source: Urology. May2025, Vol. 199, p1-10. 10p.

Reply to Editorial Comment on "Homologous Recombination Repair Mutations, Next-generation Sequencing Testing, and Treatment Progression by Race Among Patients With Metastatic Castration-sensitive Prostate Cancer".

Authors: Shore, Neal¹ (AUTHOR) nshore@auclinics.com

Source: Urology. May2026, Vol. 211, p51-52. 2p.

Evaluating the Importance of Practice-level Factors on Adherence to Prostate Cancer Treatment Guidelines in Urology.

Authors: Shore, Neal Brown, Gordon Lowentritt, Benjamin et al.

Source: Urology. Feb2025, Vol. 196, p147-154. 8p.

Enzalutamide in Biochemically Recurrent Prostate Cancer - THE AUTHORS REPLY.

Authors: Shore, Neal D. Freedland, Stephen J.

Source: New England Journal of Medicine. 4/23/2026, Vol. 394 Issue 16, p1661-1662. 2p.

Reply to Xianghu Meng, Yibo Hua, and Rijin Song's Letter to the Editor re: Stephen J. Freedland, John P. Mulhall, Martin Gleave, et al. Effects of Enzalutamide on the Sexual Activity of Patients with Biochemically Recurrent Prostate Cancer: A Post Hoc Analysis of Patient-reported Outcomes in the EMBARK Study. Eur Urol 2025;87:507–11

Authors: Freedland, Stephen J. Shore, Neal

Source: European Urology. Apr2026, Vol. 89 Issue 4, pe94-e95. 2p.

Effects of Prior Local Therapy by Radical Prostatectomy or Radiotherapy on the Efficacy and Quality of Life of Patients Treated With Darolutamide in ARAMIS.

Authors: Saar, Matthias Fizazi, Karim Shore, Neal D. et al.

Source: Cancer Medicine. Jan2026, Vol. 15 Issue 1, p1-11. 11p.

177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial.

Authors: Morris, Michael J Castellano, Daniel Herrmann, Ken et al.

Source: Lancet. 9/28/2024, Vol. 404 Issue 10459, p1227-1239. 13p.

Subjects: Prostate-specific membrane antigen, Castration-resistant prostate cancer, Androgen receptors, Progression-free survival, Overall survival, Medical screening

Is Quality of Life Impacted for Patients With HighRisk Biochemical Recurrence When Enzalutamide Is ­Prescribed?

Authors: Freedland, Stephen J. Shore, Neal D.

Source: AUANews. Sep2024, Vol. 29 Issue 9, p6-7. 2p.

Current and Future Management of Locally Advanced and Metastatic Prostate Cancer.

Authors: Shore, Neal D.¹

Source: Reviews in Urology. 2020, Vol. 22 Issue 3, p110-123. 14p.

Management of Low-grade Upper Tract Urothelial Carcinoma: An Unmet Need.

Authors: Raman, Jay Shore, Neal D.

Source: Reviews in Urology. 2020, Vol. 22 Issue 1, p1-8. 8p.

Preserving Independent Urology: LUGPA's First Decade.

Authors: Shore, Neal D. Kapoor, Deepak A. Goldfischer, Evan R. et al.

Source: Reviews in Urology. 2019, Vol. 21 Issue 2/3, p102-108. 7p.

BRCA Mutations in Prostate Cancer: What Do I Need to Know?

Authors: Shore, Neal Nielsen, Sarah

Source: AUANews. Apr2021, Vol. 26 Issue 4, p51-53. 3p.